Sanofi Consumer Healthcare India Ltd
₹ 4,780
-0.76%
25 Nov
3:40 p.m.
- Market Cap ₹ 11,009 Cr.
- Current Price ₹ 4,780
- High / Low ₹ 5,954 / 4,360
- Stock P/E 51.2
- Book Value ₹ 112
- Dividend Yield 1.15 %
- ROCE 111 %
- ROE 83.8 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 42.3 times its book value
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Loading peers table ...
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
| Dec 2023 8m | Dec 2024 | TTM | |
|---|---|---|---|
| 555 | 724 | 798 | |
| 337 | 454 | 517 | |
| Operating Profit | 219 | 271 | 281 |
| OPM % | 39% | 37% | 35% |
| 2 | -15 | 22 | |
| Interest | 0 | 4 | 2 |
| Depreciation | 2 | 4 | 9 |
| Profit before tax | 219 | 247 | 293 |
| Tax % | 25% | 27% | |
| 165 | 181 | 218 | |
| EPS in Rs | 78.59 | 94.62 | |
| Dividend Payout % | 6% | 70% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 8% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 1% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 84% |
Balance Sheet
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | Jun 2025 | |
|---|---|---|---|
| Equity Capital | 2 | 23 | 23 |
| Reserves | 206 | 250 | 234 |
| 0 | 20 | 28 | |
| 138 | 138 | 137 | |
| Total Liabilities | 345 | 431 | 422 |
| 5 | 29 | 42 | |
| CWIP | 3 | 1 | 0 |
| Investments | 0 | 0 | 0 |
| 338 | 402 | 380 | |
| Total Assets | 345 | 431 | 422 |
Cash Flows
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | |
|---|---|---|
| -0 | 439 | |
| 0 | 2 | |
| 2 | -116 | |
| Net Cash Flow | 2 | 325 |
Ratios
Figures in Rs. Crores
| Dec 2023 | Dec 2024 | |
|---|---|---|
| Debtor Days | 21 | 7 |
| Inventory Days | 232 | 80 |
| Days Payable | 144 | 138 |
| Cash Conversion Cycle | 109 | -51 |
| Working Capital Days | 134 | -33 |
| ROCE % | 111% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Nov - Newspaper publication for the quarter and nine months ended Unaudited Financial Results 30 September 2025
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
12 Nov - Q3'25 revenue ₹2,339m (+46% YoY); PAT ₹629m (+40%); results approved Nov 12, 2025.
- Results-Financial Results For September 30, 2025 12 Nov
-
Board Meeting Outcome for Outcome Of Board Meeting Held On Wednesday, 12Th November 2025
12 Nov - Board approved Q3/9M results: Q3 revenue ₹2,339m, PAT ₹629m; limited review unmodified.
-
Board Meeting Intimation for Board Meeting Intimation For Consideration And Approval Of Unaudited Financial Results For The Quarter And Nine Months Ended 30Th September 2025
5 Nov - Board meeting on 12 Nov 2025 to approve unaudited results for quarter and nine months ended 30 Sep 2025.
Business Overview:[1][2]
SCHIL was formed following its demerger from Sanofi India Limited, to establish a standalone Consumer Healthcare (CHC) business. It operates in the Consumer Healthcare (CHC) sector, providing self-care solutions across various health categories including allergy relief, pain management, and wellness